Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

305.96 +3.36 (+1.11%)
Official Closing Price Updated: 4:10 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Google, Tesla Rival XPeng Lead 5 Stocks Near Buy Zones
A FANG giant and Tesla rival are among this diverse group. 
Via Investor's Business Daily
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
3 Pharma Stocks That Could Make You Richer in November (and Beyond)
Two of them have already been big winners for investors this year. 
Via The Motley Fool
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... 
Via Benzinga
Earnings Scheduled For October 26, 2021
Companies Reporting Before The Bell • Veoneer (NYSE:VNE) is likely to report quarterly loss at $0.83 per share on revenue of $408.69 million. • Aarons (NYSE:AAN)... 
Via Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
What Investors Should Like About Eli Lilly's Q3 Update
Lilly reported solid growth, but its pipeline updates could be even more interesting. 
Via The Motley Fool
Lilly Stock Receives Key IBD Stock Rating Upgrade; Looking To Extend Its Long Run Higher
Lilly stock's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks. 
Via Investor's Business Daily
Why Eli Lilly Shares Traded Higher Today
Eli Lilly And Co (NYSE: LLY) traded higher Tuesday after the company announced it will supply 614,000 additional doses of bamlanivimab with etesevimab to the U.S. government... 
Via Benzinga
Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients
Metacrine Inc (NASDAQ: MTCR) reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly And Co's (NYSE: LLY) Jardiance... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022
Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic... 
Via Benzinga
Eli Lilly Pitches Alzheimer Drug to the FDA, Aiming to Leapfrog Biogen
It's an exciting if turbulent, and rather cutthroat, time in the world of Alzheimer's drug research. In June, the FDA greenlit Biogen's... 
Via The Motley Fool
Exposures Product Safety
Tuesday Market Coverage
Thermo Electron fell on the publication of its social responsibility report today. 
Via Talk Markets
Eli Lilly and Company (LLY) Q3 2021 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Microsoft and Alphabet Scheduled to Announce Earnings After the Closing Bell
The S&P 500 (SPX) is looking to build on Monday’s new all-time high. Stock futures are pointing higher before the open as more mega-cap Tech stocks are slated... 
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Posts Mixed Third Quarter, But Raises 2021 Sales Guidance
Eli Lilly's third-quarter earnings narrowly missed, though sales came in ahead. 
Via Investor's Business Daily
Eli Lilly Q3 Earnings Beat Estimates, Boosts FY21 Guidance On Higher COVID-19 Therapy Sales
Eli Lilly And Co (NYSE: LLY) has posted Q3 sales of $6.77 billion, beating the consensus of $5.70 billion and increasing 18% Y/Y. Higher sales were driven by a 17... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M... 
Via Benzinga
Eli Lilly: Q3 Earnings Insights
Eli Lilly (NYSE:LLY) reported its Q3 earnings results on Tuesday, October 26, 2021 at 06:25 AM. Here's what investors need to know about the announcement. Earnings Eli... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Rise Ahead Of Big Earnings
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at record highs in the previous session. Investors are... 
Via Benzinga
Topics Stocks
Exposures US Equities
7 Stocks To Watch For October 26, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects General Electric Company (NYSE: GE) to report quarterly earnings at $0.43 per share on revenue of... 
Via Benzinga
Earnings Preview For Eli Lilly
Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Tuesday, 2021-10-26. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Key takeaways Four rounds of fundraising together with IPO proceeds have given the Abbisko a cumulative war chest of almost $500 million Company is betting a significant portion... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Price Over Earnings Overview: Eli Lilly
In the current market session, Eli Lilly Inc. (NYSE:LLY) is trading at $240.60, after a 0.23% decrease. However, over the past month, the stock spiked by 3.94%, and... 
Via Benzinga
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach. 
Via Investor's Business Daily
Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?
Molnupiravir seems likely to shake up the COVID-19 antibody therapy market. 
Via The Motley Fool
Exposures COVID-19
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
Could This Be the Next Blockbuster Indication for Eli Lilly?
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.